Thermo Fisher Scientific posts 9% Q3 revenue growth and 15% EPS beat, raises 2026 outlook
Thermo Fisher Scientific reported third‑quarter 2026 revenue of $12.14 billion, up 9% year over year, and adjusted earnings per share of $6.68, a 15% increase. GAAP EPS rose 9% to $4.64. The company completed the divestiture of its microbiology business, launched new products and partnerships, and announced it will raise its full‑year 2026 revenue guidance to $47.7‑$48.2 billion and adjusted EPS guidance to $25.13‑$25.43. Updated guidance will be provided during the earnings call on October 21.
Why it matters
The higher revenue and earnings beat, together with the raised full‑year guidance, suggest stronger growth momentum and may support a higher valuation for the stock (the company said it will provide the updated guidance during the call). Analysts note the outlook lift as a positive catalyst for investors.
Key facts
- 1Q3 2026 revenue was $12.14 billion, an increase of 9% from the prior year quarter. stocktitan.net
- 2GAAP diluted EPS for Q3 2026 was $4.64, up 9% year over year. stocktitan.net
- 3Adjusted EPS for Q3 2026 was $6.68, up 15% from the prior year quarter. stocktitan.net
- 4Organic revenue growth for the quarter was 6% (excluding acquisitions, divestitures and currency effects). finance.yahoo.com
- 5Adjusted operating margin expanded to 24.5%, compared with 23.3% a year earlier. finance.yahoo.com
- 6The company completed the divestiture of its microbiology business during the quarter. finance.yahoo.com
Summary written by AlphAI AI Desk from 20 of 31 sources. Not investment advice. Figures are as stated by the linked sources.